When paychecks stop, a portfolio has to pull its own weight, and the 10-year Treasury now sets a brutally high bar for any dividend stock trying to justify its place in a retirement account.
Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing ...
Generate Capital closed a $154.5 million tax equity commitment with SOLCAP, KeyState's tax equity investment platform, ...
<?xml encoding="utf-8" ?> Generate Biomedicines Inc. GENB and Zealand Pharma A/S announced a strategic partnership Tuesday to ...
Hold: $1.2bn Zealand obesity deal, GB-0895 Phase 3 asthma readout vs Tezspire, cash burn risks, AI platform optionality—read ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Oct 13 (Reuters) - Danish obesity-drug developer Zealand Pharma has partnered with US biotechnology company Generate ...
Integrating Generate’s waste-to-value solutions businesses into a single platform enables more comprehensive sustainability and climate solutions, supporting market acceleration SAN FRANCISCO — ...
No. 20 / 2026Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics ...
Generate Capital ("Generate"), a leading investor, owner and operator of critical infrastructure today announced the expansion of its financing partnership with Zum, a technology-driven student ...
Zealand Pharma partners with Generate Biomedicines in an AI-driven obesity drug deal worth up to $1.2 billion in milestones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results